Corcept Therapeutics
149 COMMONWEALTH DRIVEMENLO PARK CA 94025 USA
P: 650-327-3270
http://www.corcept.com
Sectors & Indices
Sector
Industry
Employees
Profile
Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery.
Key Executives
Name | Title |
---|---|
Joseph K. Belanoff | CEO/Co-Founder/Director/President |
G. Charles Robb | Other Executive Officer/Secretary |
Atabak Mokari | CFO/Treasurer |
Sean Maduck | President, Divisional |
Joseph Douglas Lyon | Chief Accounting Officer |
Hazel Hunt | Chief Scientific Officer |
William Guyer | Other Executive Officer |